|  |  |  |  |
| --- | --- | --- | --- |
| ***Cohort 1*** | | | |
|  | **Combination ipilimumab and nivolumab-related colitis**  **(IN-C)** | **Combination ipilimumab and nivolumab treated**  **with nil adverse events**  **(IN-NAE)** | **p value** |
| ***Number (N)*** | 6 | 6 | N/A |
| ***Age, median years (inter-quartile range)*** | 66 (56-70) | 56 (41-63) | 0.22 |
| ***Sex (N ad % Male)*** | 4 (67) | 2 (33) | 0.25 |
| ***Melanoma Stage (N)***  ***IIIB***  ***IIIC***  ***IV*** | 1  1  4 | 2  0  4 | 0.51 |
| ***Visceral Metastases (N and %)*** | 5 (83) | 5 (83) | >0.99 |
| ***Serum lactate dehydrogenase (LDH) median U/L (interquartile range)*** | 284 (214-346) | 235 (203-443) | 0.70 |
| ***Duration of IN-C (months)*** | 1 (1-2) | N/A | N/A |
| ***Colitis treatment (N)***  ***IV Methylprednisone***  ***Mycophenolate Mofetil***  ***Infliximab***  ***Vedolizumab***  ***Colectomy*** | 2  1  2  1  0 | N/A | N/A |

**Table Ia: Clinical characteristics of Cohort 1 IN-C and IN-NAE groups.**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Cohort 1*** | | | |
|  | **Healthy volunteers** | **Ulcerative Colitis** | **p value** |
| ***Number (N)*** | 6 | 6 | N/A |
| ***Age, median years (interquartile range)*** | 67(50-78) | 36 (25-46) | 0.09 |
| ***Sex (N and %Male)*** | 2 (33) | 3 (50) | 0.56 |
| ***Duration of ulcerative colitis (median years and interquartile range)*** | N/A | 4 (3-7) | N/A |
| ***Treatment to date (N)***  ***Mesalazine***  ***Azathioprine***  ***Methotrexate***  ***Infliximab***  ***Adalimumab*** | N/A | 3  1  0  1  1 | N/A |

**Table Ib: Clinical characteristics of Cohort 1 Healthy Volunteers and Ulcerative colitis groups.**

|  |  |  |  |
| --- | --- | --- | --- |
| ***Cohort 1*** | | | |
|  | **Ulcerative colitis** | **Combination ipilimumab and nivolumab-related colitis (IN-C)** | **p value** |
| ***Number (N)*** | 6 | 6 | N/A |
| ***Age, median years (interquartile range)*** | 36 (25-46) | 66 (56-70) | <0.01 |
| ***Sex (N and %Male)*** | 3 (50) | 4 (67) | 0.56 |
| ***Duration of colitis (months)*** | 1 (1-2) | 48 (36-84) | <0.01 |
| ***Endoscopic findings***  ***(UCEIS score)***  ***0***  ***1***  ***2***  ***3***  ***4***  ***5***  ***6***  ***7***  ***8*** | 0  1  0  1  1  3  0  0  0 | 0  2  0  1  1  2  0  0  0 | 0.91 |
| ***Histological findings***  ***Diffuse mild colitis***  ***Lymphocytic colitis***  ***Mild to moderate active UC with ulcers***  ***Mild active chronic proctocolitis***  ***Mild immunotherapy-related colitis***  ***Moderate immunotherapy-related colitis***  ***Moderate active chronic colitis***  ***Severe active UC*** | 1  0  1  2  0  0  1  1 | 0  1  0  0  2  2  1  0 | N/A |
| ***Nancy Score***  ***0***  ***1***  ***2***  ***3***  ***4*** | 0  0  2  2  2 | 0  2  1  3  0 | 0.21 |

`**Table Ic: Comparison of Cohort 3 UC and IN-C clinical, endoscopic and histopathologic findings.**